COVID-19: Eight-week gap between first and second Pfizer vaccine doses 'a sweet spot', study finds | UK News | Sky News
CDC changes guidance and advises longer interval between vaccine doses | Coronavirus | The Guardian
COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 | MMWR
Johnson & Johnson (Janssen) COVID-19 vaccine: Side effects
Clinical Guidance for COVID-19 Vaccination | CDC
Biden Administration Expected to Call for Covid-19 Vaccine Booster Shots - WSJ
Vaccines | Free Full-Text | Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine | HTML
وزارة الصحة العامة on Twitter: "MOPH Begins Giving COVID-19 Vaccine Booster Doses for high-risk Individuals Who Received Their Second Dose More than Eight Months Ago https://t.co/VE9FMxlNxp https://t.co/O2H6mFaaBr" / Twitter
NHS on Twitter: "Second doses of the COVID-19 vaccine are being accelerated for all over 40's. You can now receive your second dose eight weeks after your first. 40 or over? Rebook
U.S. Recommending Third Dose of COVID Vaccine After Eight Months | MDVIP
China's COVID vaccines have been crucial — now immunity is waning
COVID-19 Vaccine :: Salford CCG
Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects | Thorax
Your Questions On The COVID-19 Vaccine | SRUK
Parents Grapple With How Long to Wait for Their Children's Second Shots - The New York Times
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two- dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results) - ACR Meeting Abstracts
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine | Nature Communications
Pfizer testing 3rd COVID vaccine dose for kids under 5 after setback | The Times of Israel
J&J Booster Raises Antibody Levels, Good After 8 Months: Study
Spirulina platensis prevents oxidative stress and inflammation promoted by strength training in rats: dose-response relation study | Scientific Reports
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden - The Lancet
CDC updates vaccine dose timing recommendation; Sanofi and GSK to seek FDA authorization for COVID-19 vaccine | AHA News
